Former President of Eli Lilly Research Labs and Head of R&D Dr. Jan Lundberg invests in Sigrid Therapeutics and joins the Company’s Scientific Advisory Board
Stockholm, Sweden June 1st , 2020. Sigrid Therapeutics, a Swedish clinical stage technology company specializing in prevention of type-2 diabetes and treatment of obesity, today announced that internationally renowned pharmaceutical R&D leader, Dr. Jan Lundberg has joined the Company as an investor and member of the Scientific Advisory Board. The appointment follows shortly after the publication of additional proof of concept for Sigrid’s medical device SiPore15TM for preventing diabetes and obesity.
Dr. Jan Lundberg has more than 20 years of leadership experience from executive positions in the global pharmaceutical companies AstraZeneca (1996-2009) and Eli Lilly (2010-2018). He has overseen the development of more than 200 candidate drugs, with 25 approved products across multiple therapeutic areas. Before joining AstraZeneca, Dr. Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden. His research achievements led to the publication of 500 articles in peer reviewed scientific journals.
“Sigrid has developed a very promising technology with the potential to improve the lives of millions of people suffering from obesity and at risk of developing type 2 diabetes. I am excited to join the Company at this stage of development and look forward to contributing to the team’s continued success”, says Dr. Jan Lundberg.
“We are absolutely delighted to welcome Dr. Jan Lundberg as an investor and member of Sigrid’s Scientific Advisory Board”, says Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics. “Dr. Lundberg’s vast R&D and business experience will be invaluable in advancing our first product to market within the next 2 years.
In addition to his considerable Big Pharma experience, Dr. Lundberg serves on the boards of Ardelyx, Metabolon, TB Alliance, Imaging Analysis Group, Anocca and Betagenon. He has also been a member of several governmental committees in both the European Union and the United States.
For more information, please contact:
Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone +46 72 389 3396,
Email: sana@sigridthx.com.
About Sigrid Therapeutics
Sigrid Therapeutics (Sigrid) is a clinical-stage technology startup pioneering a new class of engineered materials to prevent and treat metabolic disease and disorders, including type 2 diabetes. The Company’s lead product candidate, SiPore15TM, is an orally-administered medical device based on the Company’s proprietary platform technology, SiPore15TM. Designed to act locally in the gut, SiPore15TM, consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms SiPore15TM:’s beneficial effects on a range of metabolic parameters and its excellent safety profile. Upon its approval, SiPore15TM will be the first medical device available for reduction of blood sugar levels in people at risk of developing type 2 diabetes. https://www.sigridthx.com/.
